dihexa safety human trials Dihexa: Mechanism, Effects & Research Studies DIHEXA | Peptide Synthetic |

Patients who should not receive BPC-157 include: those with active or recent malignancies (due to angiogenic concerns), pregnant or breastfeeding women (no reproductive toxicology data in humans), patients on anticoagulation therapy (theoretical bleeding risk from angiogenesis at ulcer sites), and minors (no pediatric data of any kind)

Bhandarkar A, Bhat S, Kapoor N

You know what another one is

The prevalence of cobalamin deficiency among vegetarians assessed by serum vitamin B12: A review of literature

Overall, BPC-157 has been suggested in various studies to potentially help with healing joint, tendon, and muscle tissue, as well as nerve tissue

You well know, the quality of the provider matters, someone who takes a full history, understands mechanisms, and evaluates risk can actually assess concerns instead of reacting to them